NCT00603642已完成3 期
A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 34
- 主要终点
- Weeks With Weekly Platelet Response
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Japanese patients with diagnosis of ITP according to the diagnostic criteria proposed by Research Committee for Idiopathic Hematopoietic Disorders of the Ministry of Health, Labour and Welfare [MHLW] (revised in 1990) at least 6 months before the first screening visit
- •The mean of the 3 scheduled platelet counts taken at the scheduled visits during the screening period must be ≤ 30 x 10^9/L, with no individual count > 35 x 10^9/L
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Subjects must be ≥ 20 years of age at the time of obtaining the informed consent
- •Have received at least 1 prior treatment for ITP
- •If known Helicobacter pylori positive, having completed one course of Helicobacter pylori eradication therapy at least 12 weeks before the first screening visit
- •A hemoglobin value taken at scheduled visit during the screening period must be ≥ 10 g/dL
- •A serum creatinine concentration taken at scheduled visit during the screening period must be ≤ 2 mg/dL
- •Adequate liver function, as evidenced by a total bilirubin taken at scheduled visit during the screening period ≤ 1.5 times of the upper limit of the normal range (except for patients with a confirmed diagnosis of Gilbert's Disease) or an alanine aminotransferase and aspartate aminotransferase taken at the screening visit ≤ 3 times of the upper limit of the normal range
排除标准
- •Any known history of bone marrow stem cell disorder. Any abnormal bone marrow findings other than those typical of ITP.
- •Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before the first screening visit.
- •Documented diagnosis of arterial thrombosis (eg, stroke, transient ischemic attack, or myocardial infarction); history of venous thrombosis (eg, deep vein thrombosis, pulmonary embolism) and receiving anticoagulation therapy at the first screening visit.
- •Documented diagnosis of anti phospholipid antibody syndrome
- •Currently receiving any treatment for ITP except oral corticosteroids, azathioprine and/or danazol administered at a constant dose and schedule from at least 4 weeks prior to the first screening visit
- •Received intravenous immunoglobulin, anti D immunoglobulin, or any drug administered to increase platelet counts (eg, immunosuppressants except azathioprine) within 2 weeks before the first screening visit
- •Have had a splenectomy for any reason within 12 weeks before the first screening visit
- •Past or present participation in any study evaluating pegacaristim (polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor, KRN9000), Eltrombopag (SB 497115), recombinant human thrombopoietin, AMG 531, or other Mpl stimulation product
- •Received hematopoietic growth factors (eg, granulocyte colony stimulating factor, macrophage colony stimulating factor, erythropoietin, interleukin 11) for any reason within 4 weeks before the first screening visit
- •Received any anti malignancy agents (eg, cyclophosphamide, 6 mercaptopurine, vincristine, vinblastine, Interferon alfa) for any reason within 8 weeks before the first screening visit
- •Received any monoclonal antibody drugs (eg, rituximab) for any reason within 14 weeks before the first screening visit
- •Less than 4 weeks since receipt of any therapeutic drug or device that is not MHLW approved for any indication before the first screening visit
- •Pregnant or breast feeding
- •Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator
- •Known severe drug hypersensitivity
- •Concerns for subject's compliance with the protocol
研究组 & 干预措施
AMG 531
Placebo Comparator
Double blinded placebo-controlled study
干预措施: AMG 531 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Weeks With Weekly Platelet Response
时间窗: 12 weeks (Weeks 2 - 13)
Number of weeks with weekly platelet response. A weekly platelet response is defined as a platelet count of ≥ 50 x 10\^9/L on a weekly scheduled dose day from week 2 to week 13.
次要结局
- Weeks With Platelet Count Between 50 and 200(12 weeks (Weeks 2 - 13))
- Change From Baseline in Mean of Last 4 Weekly Platelet Counts(12 weeks (Weeks 2 - 13))
- Rescue Medication(s)(12 weeks (Weeks 2 - 13))
- Increased Platelet Count From Baseline of at Least 20 x 10^9/L(Baseline, 12 weeks (Weeks 2 - 13))
研究者
相似试验
已完成
2 期
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidMyelodysplastic SyndromesThrombocytopeniaNCT00418665Amgen39
已完成
2 期
A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled AsthmaAsthmaNCT01199289Amgen315
已完成
2 期
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled AsthmaAsthmaNCT01018550Amgen397
已完成
2 期
Phase II Study to Evaluate the Efficacy of AMG 317AsthmaNCT00436670Amgen294
已完成
2 期
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic AnemiaAplastic AnemiaNCT02094417Kyowa Kirin Korea Co., Ltd.35